Fibrinogen concentrate in surgery

Blood Transfusion

Volumn 15, Issue 3, 2017, Pages 215-217

  Marano, Giuseppe ^a   Mengoli, Carlo ^a   Franchini, Massimo ^a,b   Vaglio, Stefania ^a,c   Gentili, Sara ^a   Pupella, Simonetta ^a   Liumbruno, Giancarlo M ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN CONCENTRATE; FIBRINOGEN; HEMOSTATIC AGENT;

ANTICOAGULANT THERAPY; ATTRIBUTABLE RISK; BLEEDING; CARDIOPULMONARY BYPASS; CORONARY ARTERY DISEASE; CRYOPRECIPITATE; CYSTECTOMY; ERYTHROCYTE TRANSFUSION; GRAFT RECIPIENT; HEART INFARCTION; HUMAN; LIVER GRAFT; META ANALYSIS (TOPIC); MORTALITY; NOTE; POSTPARTUM HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGERY; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; THROMBOSIS; AORTA;

AORTA; FIBRINOGEN; HEMOSTATICS; HUMANS;

EID: 85020126154     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2017.0362-16     Document Type: Note

References (33)

1. Mosesson MW. Fibrinogen and fibrin structure and function. J Thromb Haemost 2005; 3: 1894-904.
2. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: A primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261-74.
3. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: A review of critical levels and replacement therapy. Transfusion 2014; 54: 1389-405.
4. Franchini M, Lippi G. Fibrinogen replacement therapy: A critical review of the literature. Blood Transfus 2012; 10: 23-7.
5. Vaglio S, Prisco D, Biancofiore G, et al. Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus 2016; 14: 23-65.
6. Liumbruno GM, Bennardello F, Lattanzio A, et al. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party. Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period. Blood Transfus 2011; 9: 19-40.
7. Liumbruno GM, Bennardello F, Lattanzio A, et al. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party. Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period. Blood Transfus 2011; 9: 189-217.
8. Liumbruno GM, Bennardello F, Lattanzio A, et al. Italian Society of Transfusion Medicine and Immunohaematology Working Party. Recommendations for the transfusion management of patients in the peri-operative period. III. The post-operative period. Blood Transfus 2011; 9: 320-35.
9. Liumbruno GM, Vaglio S, Capuzzo E, Franchini M. Fibrinogen concentrate as haemostatic therapy in acquired bleeding disorders: not only a question of dosing strategies and thresholds. Blood Transfus 2015; 13: 159-60.
10. Wikkelsø A, Lunde J, Johansen M, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev 2013; 8: CD008864.
11. Fominskiy E, Nepomniashchikh VA, Lomivorotov VV, et al. Efficacy and safety of fibrinogen concentrate in surgical patients: A meta-Analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2016; 30: 1196-204.
12. Cui Y, Hei F, Long C, et al. Perioperative monitoring of thromboelastograph on blood protection and recovery for severely cyanotic patients undergoing complex cardiac surgery. Artif Organs 2010; 34: 955-60.
13. Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: A randomized, placebo-controlled clinical trial. J Thromb Haemost 2009; 7: 795-802.
14. Galas FR, de Almeida JP, Fukushima JT, et al. Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: A randomized pilot trial. J Thorac Cardiovasc Surg 2014; 148: 1647-55.
15. Jeppsson A, Waldén K, Roman-Emanuel C, et al. Preoperative supplementation with fibrinogen concentrate in cardiac surgery: A randomized controlled study. Br J Anaesth 2016; 116: 208-14.
16. Karlsson M, Ternström L, Hyllner M, et al. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost 2009; 102: 137-44.
17. Lancé MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: A prospective randomized intervention trial. Vox Sang 2012; 103: 25-34.
18. Najafi A, Shariat Moharari R, Orandi AA, et al. Prophylactic administration of fibrinogen concentrate in perioperative period of total hip arthroplasty: A randomized clinical trial study. Acta Med Iran 2014; 52: 804-10.
19. Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40-50.
20. Ranucci M, Baryshnikova E, Crapelli GB, et al. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015; 4: E002066.
21. Sabate A, Gutierrez R, Beltran J, et al. Impact of pre-emptive fibrinogen concentrate on transfusion requirements in liver transplantation: A multicenter, randomized, double-blind, placebo-controlled trial. Am J Transplant 2016; 16: 2421-9.
22. Sadeghi M, Atefyekta R, Azimaraghi O, et al. A randomized, double blind trial of prophylactic fibrinogen to reduce bleeding in cardiac surgery. Braz J Anesthesiol 2014; 64: 253-7.
23. Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion 2014; 54: 109-18.
24. Wikkelsø AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: Randomized controlled trial. Br J Anaesth 2015; 114: 623-33.
25. Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): A double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117: 41-51.
26. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-Analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007; 7: 5.
27. Validity of methods of meta-Analysis for rare events. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (2011). Higgins JPT, Green S. Eds. Available at: http://handbook.cochrane.org/chapter-16/16-9-5-validity-of-methods-of-meta-Analysis-for-rare-events.htm. Accessed on 15/12/2016.
28. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: A comparison of the performance of meta-Analytical methods with rare events. Statist Med 2007; 26: 53-77.
29. Cai T, Parast L, Ryan L. Meta-Analysis for rare events. Stat Med 2010; 29: 2078-89.
30. Boehning D, Mylona K, Kimber A. Meta-Analysis of clinical trials with rare events. Biom J 2015; 57: 633-48.
31. Tian L, Cai T, Pfeffer MA, et al. Exact and efficient inference procedure for meta-Analysis and its application to the analysis of independent 2x2 tables with all available data but without artificial continuity correction. Biostatistics 2009; 10: 275-81.
32. Chen DG, Peace KE. Applied Meta-Analysis with R. Boca Raton: CRC Press; 2013. p. 266.
33. Liu D. Combining information for heterogeneous studies and rare events studies: A confidence distribution approach. Dissertation submitted to Rutgers, The State University of New Jersey; 2012. Available at: https://rucore.libraries.rutgers.edu/rutgers-lib/37435/. Accessed on 15/12/2016.